Journal of Clinical Oncology, Vol 15, 691-700, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer

BG Haffty, B Ward, P Pathare, R Salem, C McKhann, M Beinfield, D Fischer and M Reiss
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520-8040, USA. bruce.haffty@yale.edu

PURPOSE: The purpose of this study was (1) to review systemic therapy practice patterns to assess how information regarding nodal status currently influences systemic therapy decisions, and (2) to review long- term outcome of patients who do not undergo axillary dissection compared with patients who do. METHODS AND MATERIALS: For the current practice patterns portion of the study, the records of 292 patients who presented in the past 3 years with invasive breast cancer and underwent conservative surgery were reviewed to determine systemic therapy administered with respect to patient age, primary tumor size, clinical nodal status, and presenting symptoms. For the long-term outcome portion of the study, the records of 955 patients with invasive breast cancer who underwent conservative surgery and radiation therapy before December 1989 were reviewed. Patient characteristics and outcome of those patients who underwent axillary dissection (n = 565, 59%) were compared with a cohort of patients treated during the same era who did not undergo axillary dissection (n = 390, 41%). RESULTS: For the current practice-patterns cohort, information regarding nodal status appeared to influence adjuvant systemic therapy for those patients less than 50 years of age and for those patients with palpable masses who were older than 50. Patients older than 50 with nonpalpable mammographically detected tumors have a low probability of nodal involvement and information regarding nodal status rarely changed therapy in this group of patients. In the long-term outcome study, there were no significant differences in the rates of distant metastasis, disease-free survival, or overall survival between those patients who underwent lymph node dissection and those who did not. CONCLUSION: For selected patients, axillary lymph node dissection appears to have little influence on subsequent management and long-term outcome. These data suggest that it is time to reassess the role of axillary lymph node dissection in patients who undergo conservative surgery and radiation therapy.

This article has been cited by other articles:

				G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]

				P. J. Lovrics, V. Chen, G. Coates, S. D. Cornacchi, C. H. Goldsmith, C. Law, M. N. Levine, K. Sanders, and V. R. Tandan A Prospective Evaluation of Positron Emission Tomography Scanning, Sentinel Lymph Node Biopsy, and Standard Axillary Dissection for Axillary Staging in Patients with Early Stage Breast Cancer Ann. Surg. Oncol., September 1, 2004; 11(9): 846 - 853. [Abstract] [Full Text] [PDF]

				G. Mariani, L. Moresco, G. Viale, G. Villa, M. Bagnasco, G. Canavese, J. Buscombe, H. W. Strauss, and G. Paganelli Radioguided Sentinel Lymph Node Biopsy in Breast Cancer Surgery J. Nucl. Med., August 1, 2001; 42(8): 1198 - 1215. [Abstract] [Full Text] [PDF]

				M. Greco, F. Crippa, R. Agresti, E. Seregni, A. Gerali, R. Giovanazzi, A. Micheli, S. Asero, C. Ferraris, M. Gennaro, et al. Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography: Clinical Evaluation and Alternative Management J Natl Cancer Inst, April 18, 2001; 93(8): 630 - 635. [Abstract] [Full Text] [PDF]

				S. R. Galper, S. J. Lee, M. L. Tao, S. Troyan, C. M. Kaelin, J. R. Harris, and J. C. Weeks Patient Preferences for Axillary Dissection in the Management of Early-Stage Breast Cancer J Natl Cancer Inst, October 18, 2000; 92(20): 1681 - 1687. [Abstract] [Full Text] [PDF]

				A. E. Giuliano, P. I. Haigh, M. B. Brennan, N. M. Hansen, M. C. Kelley, W. Ye, E. C. Glass, and R. R. Turner Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node-Negative Breast Cancer J. Clin. Oncol., July 1, 2000; 18(13): 2553 - 2559. [Abstract] [Full Text] [PDF]

				M. Guenin, L. Liberman, and H. S. Cody III Sentinel Lymph Node Biopsy in Breast Carcinoma Drs Liberman and Cody respond: Radiology, June 1, 2000; 215(3): 920 - 922. [Full Text]

				G. Parmigiani, D. A. Berry, E. P. Winer, C. Tebaldi, J. D. Iglehart, and L. R. Prosnitz Is Axillary Lymph Node Dissection Indicated for Early-Stage Breast Cancer? A Decision Analysis J. Clin. Oncol., May 1, 1999; 17(5): 1465 - 1465. [Abstract] [Full Text] [PDF]

				M. C. Smitt and D. R. Goffinet Utility of Three-dimensional Planning for Axillary Node Coverage with Breast-conserving Radiation Therapy: Early Experience Radiology, January 1, 1999; 210(1): 221 - 226. [Abstract] [Full Text]